Advertisement

Adrenoceptor-stimulated inflammatory response in stress-induced serum amyloid A synthesis

  • Maria Konstandi
  • Ioannis Sotiropoulos
  • Tsutomu Matsubara
  • Foteini Malliou
  • Alexandra Katsogridaki
  • Christina E. Andriopoulou
  • Frank J. Gonzalez
Original Investigation
  • 102 Downloads

Abstract

Rationale

Stressful life events are suggested to contribute to the development of various pathologies, such as cardiovascular disorders, whose etiopathogenesis is highly associated with elevated levels of serum amyloid A (SAA) proteins. SAA synthesis in the liver is regulated by a complex network of cytokines acting independently or in concert with various hormones/stimulants including the stress-activated sympathetic nervous system.

Objective

This study aims to investigate the underlying mechanisms that regulate the stress-induced hepatic synthesis of SAA, with particular focus on adrenoceptors (AR), major components of the sympathoadrenal response to stress.

Methods and results

We demonstrated that repeated stress elevates IL-1β, IL-6, and TNFα serum levels in mice, accompanied by increased synthesis and secretion of hepatic SAA1/2 and SAA3, an effect that was blocked by AR antagonists. Moreover, stimulation of α1- and β1/2-ARs mimics the stress effect on SAA1/2 regulation, whereas α2-AR stimulation exhibits a relatively weak impact on SAA. In support of the essential cytokine contribution in the AR-agonist induced SAA production is the fact that the anti-inflammatory drug, sodium salicylate, prevented the AR-stimulated hepatic SAA1/2 synthesis by reducing IL-1β levels, whereas IL-1β inhibition with Anakinra mimics this sodium salicylate preventive effect, thus indicating a crucial role for IL-1β. Interestingly, the AR-driven SAA3 synthesis was elevated by sodium salicylate in a TNFα-dependent way, supporting diverse and complex regulatory roles of cytokines in SAA production. In contrast to α12-AR, the β1/2-AR-mediated SAA1/2 and SAA3 upregulation cannot be reversed by fenofibrate, a hypolipidemic drug with anti-inflammatory properties.

Conclusion

Taken together, these findings strongly support a critical role of the AR-stimulated inflammatory response in the hepatic SAA production under stressful conditions, highlighting distinct AR type-specific mechanisms that regulate the hepatic synthesis of SAA1/2 and SAA3.

Keywords

SAA1/2 SAA3 Stress Adrenoceptors IL-1β IL-6 TNFα 

Notes

Acknowledgments

The authors would like to thank Dr. Kristopher Krautz for his valuable technical assistance and support and Dr. Konstantinos Ritis, Professor of Immunology, for his constructive comments on these studies.

Author contributions

MK designed the experiments; MK, TM, FM, AK, and CA conducted experiments; MK, IS, and FJG performed data quantification and analysis; MK and IS wrote the manuscript, while FJG was involved in the manuscript revision.

Funding

This research was supported by the European Union (European Regional Development Fund- ERDF) and the Greek national funds through the Operational Program “THESSALY- MAINLAND GREECE AND EPIRUS-2007-2013” of the National Strategic Reference Framework (NSRF 2007–2013, Grant 346985/80753) and the National Cancer Institute Intramural Research Program.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Supplementary material

213_2018_5149_MOESM1_ESM.doc (63 kb)
ESM 1 (DOC 63 kb)

References

  1. Aich P, Potter AA, Griebel PJ (2009) Modern approaches to understanding stress and disease susceptibility: a review with special emphasis on respiratory disease. Int J Gen Med 2:19–32CrossRefGoogle Scholar
  2. Artl A, Marsche G, Lestavel S, Sattler W, Malle E (2000) Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol 20:763–772CrossRefGoogle Scholar
  3. Barneda-Zahonero B, Minano-Molina A, Badiola N, Fado R, Xifro X, Saura CA, Rodriguez-Alvarez J (2009) Bone morphogenetic protein-6 promotes cerebellar granule neurons survival by activation of the MEK/ERK/CREB pathway. Mol Biol Cell 20:5051–5063CrossRefGoogle Scholar
  4. Bryleva EY, Keaton SA, Grit J, Madaj Z, Sauro-Nagendra A, Smart L, Halstead S, Achtyes E, Brundin L (2017) The acute-phase mediator serum amyloid A is associated with symptoms of depression and fatigue. Acta Psychiatr Scand 135:409–418CrossRefGoogle Scholar
  5. Chrousos GP (2009) Stress and disorders of the stress system. Nat Rev Endocrinol 5:374–381CrossRefGoogle Scholar
  6. Collier CT, Williams PN, Carroll JA, Welsh THJ, Laurenz JC (2011) Effect of maternal restraint stress during gestation on temporal lipopolysaccharide-induced neuroendocrine and immune responses of progeny. Domest Anim Endocrinol 40:40–50CrossRefGoogle Scholar
  7. Cooper JR, Bloom FE (1996) The biochemical basis of neuropharmacology, 7th edn. Oxford University Press, New YorkGoogle Scholar
  8. Cray C, Dickey M, Brewer LB, Arheart KL (2013) Assessement of serum amyloid A levels in the rehabilitation setting in the Florida manatee (Trichechus manatus latirostris). J Zoo Wildl Med 44:911–917CrossRefGoogle Scholar
  9. Cruise JL, Knechtle SJ, Bollinger RR, Kuhn C, Michalopoulos G (1987) Alpha 1-adrenergic effects and liver regeneration. Hepatology 7:1189–1194CrossRefGoogle Scholar
  10. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B (1999) Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 274:32048–32054CrossRefGoogle Scholar
  11. Dong Z, Wu T, Qin W, An C, Wang Z, Zhang M, Zhang Y, Zhang C, An F (2011) Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Mol Med 17:1357–1364CrossRefGoogle Scholar
  12. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES (2000) The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 52:595–638PubMedGoogle Scholar
  13. Fabbri E, Moon TW (2016) Adrenergic signaling in teleost fish liver, a challenging path. Comp Biochem Physiol B Biochem Mol Biol 199:74–86CrossRefGoogle Scholar
  14. Fasshauer M, Klein J, Kralisch S, Klier M, Lossner U, Bluher M, Paschke R (2004) Serum amyloid A3 expression is stimulated by dexamethasone and interleukin-6 in 3T3-L1 adipocytes. J Endocrinol 183:561–567CrossRefGoogle Scholar
  15. Flierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma JV, Zetoune FS, McGuire SR, List RP, Day DE, Hoesel LM, Gao H, Van Rooijen N, Huber-Lang MS, Neubig RR, Ward PA (2007) Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 449:721–725CrossRefGoogle Scholar
  16. Flierl MA, Rittirsch D, Huber-Lang M, Sarma JV, Ward PA (2008) Catecholamines-crafty weapons in the inflammatory arsenal of immune/inflammatory cells or opening pandora’s box? Mol Med 14:195–204PubMedGoogle Scholar
  17. Flierl MA, Rittirsch D, Nadeau BA, Sarma JV, Day DE, Lentsch AB, Huber-Lang MS, Ward PA (2009) Upregulation of phagocyte-derived catecholamines augments the acute inflammatory response. PLoS One 4:e4414CrossRefGoogle Scholar
  18. Furchgott RF (1972) The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Blaschko H, Muecholl E (eds) Catecholamines. Springer-Verlag, New York, p 283–335Google Scholar
  19. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454CrossRefGoogle Scholar
  20. Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B, Kooistra T (2004) Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J Biol Chem 279:16154–16160CrossRefGoogle Scholar
  21. Ghezzi P, Sipe JD (1988) Dexamethasone modulation of LPS, IL-1, and TNF stimulated serum amyloid a synthesis in mice. Lymphokine Res 7:157–166PubMedGoogle Scholar
  22. Housby JN, Cahill CM, Chu B, Prevelige R, Bickford K, Stevenson MA, Calderwood SK (1999) Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine 11:347–358CrossRefGoogle Scholar
  23. Husebekk A, Skogen B, Husby G, Marhaug G (1985) Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand J Immunol 21:283–287CrossRefGoogle Scholar
  24. Jacobsen S, Andersen PH (2007) The acute phase protein serum amyloid A (SAA) as a marker of inflammation in horses. Equine Vet Educ 19:38–46CrossRefGoogle Scholar
  25. Jayaraman S, Gantz DL, Haupt C, Gursky O (2017) Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis. Proc Natl Acad Sci U S A 114:E6507–E6515CrossRefGoogle Scholar
  26. Johnson EO, Kamilaris TC, Chrousos GP, Gold PW (1992) Mechanisms of stress: a dynamic overview of hormonal and behavioral homeostasis. Neurosci Biobehav Rev 16:115–130CrossRefGoogle Scholar
  27. Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Pepine CJ, Sharaf B, Bairey Merz CN, Sopko G, Olson MB, Reis SE (2004) Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation 109:726–732CrossRefGoogle Scholar
  28. Johnson JD, Campisi J, Sharkey CM, Kennedy SL, Nickerson M, Greenwood BN, Fleshner M (2005) Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. Neuroscience 135:1295–1307CrossRefGoogle Scholar
  29. Kingman A, Pereira NL (2001) Cardiac amyloidosis. J S C Med Assoc 97:201–206PubMedGoogle Scholar
  30. Kisilevsky R (1983) Amyloidosis: a familiar problem in the light of current pathogenetic developments. Lab Investig 49:381–390PubMedGoogle Scholar
  31. Konstandi M, Johnson EO, Marselos M, Kostakis D, Fotopoulos A, Lang MA (2004) Stress-mediated modulation of B(alpha)P-induced hepatic CYP1A1: role of catecholamines. Chem Biol Interact 147:65–77CrossRefGoogle Scholar
  32. Lalchandani SG, Zhang X, Hong SS, Liggett SB, Li W, Moore BM 2nd, Miller DD, Feller DR (2004) Medetomidine analogs as selective agonists for the human alpha2-adrenoceptors. Biochem Pharmacol 67:87–96CrossRefGoogle Scholar
  33. Langer SZ (2015) Alpha2-adrenoceptors in the treatment of major neuropsychiatric disorders. Trends Pharmacol Sci 36:196–202CrossRefGoogle Scholar
  34. Lee HJ, Kim JH, Kim SW, Joo HA, Lee HW, Kim YS, Park SJ, Hong SP, Kim TI, Kim WH, Kim YH, Cheon JH (2017) Proteomic analysis of serum amyloid A as a potential marker in intestinal Behcet’s disease. Dig Dis Sci 62:1953–1962CrossRefGoogle Scholar
  35. Lohse MJ (2015) The ins and outs of adrenergic signaling. J Mol Med (Berl) 93:955–962CrossRefGoogle Scholar
  36. Lu J, Liang J, Wang JR, Hu L, Tu Y, Guo JY (2013) Acupuncture activates ERK-CREB pathway in rats exposed to chronic unpredictable mild stress. Evid Based Complement Alternat Med 2013:469765Google Scholar
  37. Ma J, Yee A, Brewer HB Jr, Das S, Potter H (1994) Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372:92–94CrossRefGoogle Scholar
  38. Madden KS, Felten SY, Felten DL, Sundaresan PR, Livnat S (1989) Sympathetic neural modulation of the immune system. I Depression of T cell immunity in vivo and vitro following chemical sympathectomy. Brain Behav Immun 3:72–89CrossRefGoogle Scholar
  39. Malle E, De Beer FC (1996) Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Investig 26:427–435CrossRefGoogle Scholar
  40. Marzi C, Huth C, Herder C, Baumert J, Thorand B, Rathmann W, Meisinger C, Wichmann HE, Roden M, Peters A, Grallert H, Koenig W, Illig T (2013) Acute-phase serum amyloid A protein and its implication in the development of type 2 diabetes in the KORA S4/F4 study. Diabetes Care 36:1321–1326CrossRefGoogle Scholar
  41. McConnell KJ, Olson KL, Delate T, Merenich JA (2009) Factors associated with recurrent coronary events among patients with cardiovascular disease. Pharmacotherapy 29:906–913CrossRefGoogle Scholar
  42. Minneman KP, Esbenshade TA (1994) Alpha 1-adrenergic receptor subtypes. Annu Rev Pharmacol Toxicol 34:117–133CrossRefGoogle Scholar
  43. Miyazaki Y, Katanasaka Y, Sunagawa Y, Hirano-Sunagawa S, Funamoto M, Morimoto E, Komiyama M, Shimatsu A, Satoh-Asahara N, Yamakage H, Wada H, Hasegawa K, Morimoto T (2016) Effect of statins on atherogenic serum amyloid a and alpha1-antitrypsin low-density lipoprotein complexes. Int J Cardiol 225:332–336CrossRefGoogle Scholar
  44. Nguyen VA, Gao B (1999) Cross-talk between alpha(1B)-adrenergic receptor (alpha(1B)AR) and interleukin-6 (IL-6) signaling pathways. Activation of alpha(1b)AR inhibits il-6-activated STAT3 in hepatic cells by a p42/44 mitogen-activated protein kinase-dependent mechanism. J Biol Chem 274:35492–35498CrossRefGoogle Scholar
  45. Nicolaides NC, Kyratzi E, Lamprokostopoulou A, Chrousos GP, Charmandari E (2015) Stress, the stress system and the role of glucocorticoids. Neuroimmunomodulation 22:6–19CrossRefGoogle Scholar
  46. Nishi S, Alchi B, Imai N, Gejyo F (2008) New advances in renal amyloidosis. Clin Exp Nephrol 12:93–101CrossRefGoogle Scholar
  47. O’Brien KD, McDonald TO, Kunjathoor V, Eng K, Knopp EA, Lewis K, Lopez R, Kirk EA, Chait A, Wight TN, deBeer FC, LeBoeuf RC (2005) Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. Arterioscler Thromb Vasc Biol 25:785–790CrossRefGoogle Scholar
  48. O’Brien K, Fitzgerald DC, Naiken K, Alugupalli KR, Rostami AM, Gran B (2008) Role of the innate immune system in autoimmune inflammatory demyelination. Curr Med Chem 15:1105–1115CrossRefGoogle Scholar
  49. Pettersson T, Konttinen YT, Maury CP (2008) Treatment strategies for amyloid A amyloidosis. Expert Opin Pharmacother 9:2117–2128CrossRefGoogle Scholar
  50. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1998) Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97:425–428CrossRefGoogle Scholar
  51. Schiller M, Bohm M, Dennler S, Ehrchen JM, Mauviel A (2006) Mitogen- and stress-activated protein kinase 1 is critical for interleukin-1-induced, CREB-mediated, c-fos gene expression in keratinocytes. Oncogene 25:4449–4457CrossRefGoogle Scholar
  52. Skogen B, Thorsteinsson L, Natvig JB (1980) Degradation of protein SAA to an AA-like fragment by enzymes of monocytic origin. Scand J Immunol 11:533–540CrossRefGoogle Scholar
  53. Sletten K, Husby G (1974) The complete amino-acid sequence of non-immunoglobulin amyloid fibril protein AS in rheumatoid arthritis. Eur J Biochem 41:117–125CrossRefGoogle Scholar
  54. Spengler RN, Allen RM, Remick DG, Strieter RM, Kunkel SL (1990) Stimulation of alpha-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J Immunol 145:1430–1434PubMedGoogle Scholar
  55. Spengler RN, Chensue SW, Giacherio DA, Blenk N, Kunkel SL (1994) Endogenous norepinephrine regulates tumor necrosis factor-alpha production from macrophages in vitro. J Immunol 152:3024–3031PubMedGoogle Scholar
  56. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A (1998) Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393:790–793CrossRefGoogle Scholar
  57. Steel DM, Whitehead AS (1994) The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid a protein. Immunol Today 15:81–88CrossRefGoogle Scholar
  58. Sternberg EM (2006) Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol 6:318–328CrossRefGoogle Scholar
  59. Tan KS, Nackley AG, Satterfield K, Maixner W, Diatchenko L, Flood PM (2007) Beta2 adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA- and NF-kappaB-independent mechanisms. Cell Signal 19:251–260CrossRefGoogle Scholar
  60. Taupin V, Gogusev J, Descampslatscha B, Zavala F (1993) Modulation of tumor-necrosis-factor-alpha, interleukin-1-beta, interleukin-6, interleukin-8, and granulocyte/macrophage colony-stimulating factor expression in human monocytes by an endogenous anxiogenic benzodiazepine ligand, triakontatetraneuropeptide—evidence for a role of prostaglandins. Mol Pharmacol 43:64–69PubMedGoogle Scholar
  61. Tracey KJ (2002) The inflammatory reflex. Nature 420:853–859CrossRefGoogle Scholar
  62. Turlo A, Cywinska A, Czopowicz M, Witkowski L, Niedzwiedz A, Slowikowska M, Borowicz H, Jaskiewicz A, Winnicka A (2015) The effect of different types of musculoskeletal injuries on blood concentration of serum amyloid A in thoroughbred racehorses. PLoS One 10:e0140673CrossRefGoogle Scholar
  63. Uhlar CM, Whitehead AS (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265:501–523CrossRefGoogle Scholar
  64. Virtanen R (1989) Pharmacological profiles of medetomidine and its antagonist, atipamezole. Acta Vet Scand Suppl 85:29–37PubMedGoogle Scholar
  65. Vittimberga FJ Jr, McDade TP, Perugini RA, Callery MP (1999) Sodium salicylate inhibits macrophage TNF-alpha production and alters MAPK activation. J Surg Res 84:143–149CrossRefGoogle Scholar
  66. Won TW (2013) Fenofibrate, a peroxisome proliferator-activated receptor alpha-agonist, blocks lipopolysaccharide-induced inflammatory pathways in mouse liver. Korean J Hepatobiliary Pancreat Surg 17:89–108CrossRefGoogle Scholar
  67. Yamazaki K, Kuromitsu J, Tanaka I (2002) Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator-activated receptor alpha agonists. Biochem Biophys Res Commun 290:1114–1122CrossRefGoogle Scholar
  68. Ye RD, Sun L (2015) Emerging functions of serum amyloid A in inflammation. J Leukoc Biol 98:923–929CrossRefGoogle Scholar
  69. Zhang N, Ahsan MH, Purchio AF, West DB (2005) Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition. J Immunol 174:8125–8134CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Maria Konstandi
    • 1
    • 2
  • Ioannis Sotiropoulos
    • 3
    • 4
  • Tsutomu Matsubara
    • 2
    • 5
  • Foteini Malliou
    • 1
  • Alexandra Katsogridaki
    • 1
  • Christina E. Andriopoulou
    • 1
  • Frank J. Gonzalez
    • 2
  1. 1.Faculty of Medicine, Department of PharmacologyUniversity of IoanninaIoanninaGreece
  2. 2.Laboratory of Metabolism, National Cancer InstituteNational Institutes of HealthBethesdaUSA
  3. 3.Life and Health Sciences Research Institute (ICVS)Medical School, University of MinhoBragaPortugal
  4. 4.ICVS/3B’s - PT Government Associate LaboratoryBragaPortugal
  5. 5.Graduate School of Medicine, Department of Anatomy and Regenerative BiologyOsaka City UniversityOsakaJapan

Personalised recommendations